Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2020

01-12-2020 | Doxycycline | Research

The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis

Authors: Qi Wang, Mengqi Luo, Bo Xiang, Siyuan Chen, Yi Ji

Published in: Respiratory Research | Issue 1/2020

Login to get access

Abstract

Background

Lymphangioleiomyomatosis (LAM) is a rare, low-grade multisystem neoplastic disease. Most LAM patients are at a high risk of losing lung function at an accelerated rate and developing progressive dyspnea. Recently, several studies have reported their experience with pharmacological treatments for LAM. Therefore, we conducted a systematic review and meta-analysis to assess the efficacy and safety of these therapies.

Methods

PubMed (Medline), EMBASE, Cochrane Library, Web of Science and EBSCO Host were searched (until March 31, 2019) for eligible prospective studies regarding LAM patients treated with pharmacological treatments. Random effect models were used for quantitative analysis.

Results

Fourteen prospective studies regarding five pharmacological treatments (including sirolimus, everolimus, doxycycline, triptorelin, and a combination therapy of sirolimus and hydroxychloroquine) were enrolled in our systematic review, and ten of them were used for the meta-analysis. Seven prospective studies reported that sirolimus was effective at improving or stabilizing lung function and alleviating renal angiomyolipoma (AML) in LAM patients. Subsequent quantitative analyses showed that during sirolimus treatment, the pooled values of lung function and 6-min walk distance (6MWD) were not significantly changed (P > 0.05), with the pooled response rate of AML being 0.62 (95% confidence intervals [CIs]: 0.43 to 0.82, I2 = 65%). Regarding everolimus, three prospective studies reported similar effects to those of sirolimus with regard to preserving lung function and reducing AMLs. The meta-analysis showed that the changes in lung function during everolimus treatment were not statistically significant (P > 0.05), while the pooled response rate of AML was 0.78 (95% CI: 0.68 to 0.88, I2 = 8%). Neither the qualitative nor the quantitative results confirmed the benefits of doxycycline or triptorelin treatment, and the effects of the combination therapy were unclear in LAM patients. Most of the adverse events during pharmacological treatments were low or moderate grade and tolerable.

Conclusions

Overall, sirolimus and everolimus were recommended for the treatment of LAM because they could stabilize lung function and alleviate renal AML. Doxycycline and triptorelin were not recommended for the treatment of LAM because no beneficial outcomes were consistently observed. The efficacy and safety of combination therapy remain to be further explored.
Appendix
Available only for authorised users
Literature
1.
McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, Steagall WK, Johnson SR, Sahn SA, Ryu JH, et al. Official American Thoracic Society/Japanese respiratory society clinical practice guidelines: Lymphangioleiomyomatosis diagnosis and management. Am J Respir Crit Care Med. 2016;194(6):748–61.PubMedPubMedCentralCrossRef
2.
3.
Harknett EC, Chang WYC, Byrnes S, Johnson J, Lazor R, Cohen MM, Gray B, Geiling S, Telford H, Tattersfield AE, et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM : monthly journal of the Association of Physicians. 2011;104(11):971–9.PubMedCrossRef
4.
Aubry MC, Myers JL, Ryu JH, Henske EP, Logginidou H, Jalal SM, Tazelaar HD. Pulmonary lymphangioleiomyomatosis in a man. Am J Respir Crit Care Med. 2000;162(2 Pt 1):749–52.PubMedCrossRef
5.
Ciftci AO, Sanlialp I, Tanyel FC, Buyukpamukcu N. The association of pulmonary lymphangioleiomyomatosis with renal and hepatic angiomyolipomas in a prepubertal girl: a previously unreported entity. Respiration; international review of thoracic diseases. 2007;74(3):335–7.PubMedCrossRef
6.
Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway A, Moss J. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest. 2004;126(6):1867–74.PubMedCrossRef
7.
Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med. 1999;160(2):628–33.PubMedCrossRef
8.
Johnson SR, Whale CI, Hubbard RB, Lewis SA, Tattersfield AE. Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax. 2004;59(9):800–3.PubMedPubMedCentralCrossRef
9.
Bee J, Fuller S, Miller S, Johnson SR. Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: a prospective national cohort study. Thorax. 2018;73(4):369–75.PubMedCrossRef
10.
Karbowniczek M, Astrinidis A, Balsara BR, Testa JR, Lium JH, Colby TV, McCormack FX, Henske EP. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med. 2003;167(7):976–82.PubMedCrossRef
11.
Chen F, Bando T, Fukuse T, Omasa M, Aoyama A, Hamakawa H, Fujinaga T, Shoji T, Sakai H, Hanaoka N, et al. Recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation. Transplant Proc. 2006;38(9):3151–3.PubMedCrossRef
12.
13.
Yu J, Astrinidis A, Henske EP. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am J Respir Crit Care Med. 2001;164(8 Pt 1):1537–40.PubMedCrossRef
14.
15.
Henske EP. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes, chromosomes & cancer. 2003;38(4):376–81.CrossRef
16.
Cai X, Pacheco-Rodriguez G, Fan QY, Haughey M, Samsel L, El-Chemaly S, Wu HP, McCoy JP, Steagall WK, Lin JP, et al. Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2010;182(11):1410–8.PubMedPubMedCentralCrossRef
17.
Kumasaka T, Seyama K, Mitani K, Souma S, Kashiwagi S, Hebisawa A, Sato T, Kubo H, Gomi K, Shibuya K, et al. Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol. 2005;29(10):1356–66.PubMedCrossRef
18.
Kumasaka T, Seyama K, Mitani K, Sato T, Souma S, Kondo T, Hayashi S, Minami M, Uekusa T, Fukuchi Y, et al. Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis. Am J Surg Pathol. 2004;28(8):1007–16.PubMedCrossRef
19.
Denoo X, Hermans G, Degives R, Foidart JM. Successful treatment of pulmonary lymphangioleiomyomatosis with progestins: a case report. Chest. 1999;115(1):276–9.PubMedCrossRef
20.
Harari S, Cassandro R, Chiodini I, Taveira-DaSilva AM, Moss J. Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis. Chest. 2008;133(2):448–54.PubMedCrossRef
21.
Tomasian A, Greenberg MS, Rumerman H. Tamoxifen for lymphangioleiomyomatosis. N Engl J Med. 1982;306(12):745–6.PubMedCrossRef
22.
Pimenta SP, Baldi BG, Kairalla RA, Carvalho CR. Doxycycline use in patients with lymphangioleiomyomatosis: biomarkers and pulmonary function response. Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia. 2013;39(1):5–15.CrossRef
23.
Chang WY, Cane JL, Kumaran M, Lewis S, Tattersfield AE, Johnson SR. A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis. Eur Respir J. 2014;43(4):1114–23.PubMedCrossRef
24.
Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358(2):140–51.PubMedPubMedCentralCrossRef
25.
Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2013;381(9869):817–24.CrossRef
26.
Zhan Y, Shen L, Xu W, Wu X, Zhang W, Wang J, Li X, Yang Y, Tian X, Xu KF. Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study. Orphanet J Rare Dis. 2018;13(1):34.PubMedPubMedCentralCrossRef
27.
Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712–6.PubMedCrossRef
28.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical research ed). 2009;339:b2535.CrossRef
29.
Higgins J, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011, Available from www.​cochrane-handbook.​org.
30.
31.
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.PubMedPubMedCentralCrossRef
32.
Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785–805.PubMedCrossRef
33.
McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595–606.PubMedPubMedCentralCrossRef
34.
35.
Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, Watson PC, Howe CJ, Doyle T, Pointon K, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Can Res. 2011;17(12):4071–81.CrossRef
36.
Goldberg HJ, Harari S, Cottin V, Rosas IO, Peters E, Biswal S, Cheng Y, Khindri S, Kovarik JM, Ma S, et al. Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. Eur Respir J. 2015;46(3):783–94.PubMedCrossRef
37.
Takada T, Mikami A, Kitamura N, Seyama K, Inoue Y, Nagai K, Suzuki M, Moriyama H, Akasaka K, Tazawa R, et al. Efficacy and safety of long-term Sirolimus therapy for Asian patients with Lymphangioleiomyomatosis. Ann Am Thorac Soc. 2016;13(11):1912–22.PubMedCrossRef
38.
El-Chemaly S, Taveira-Dasilva A, Goldberg HJ, Peters E, Haughey M, Bienfang D, Jones AM, Julien-Williams P, Cui Y, Villalba JA, et al. Sirolimus and autophagy inhibition in Lymphangioleiomyomatosis: results of a phase I clinical trial. Chest. 2017;151(6):1302–10.PubMedPubMedCentralCrossRef
39.
Cai Y, Guo H, Wang W, Li H, Sun H, Shi B, Zhang Y. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial. Orphanet J Rare Dis. 2018;13(1):43.PubMedPubMedCentralCrossRef
40.
Aghaeimeybodi F, Najafizadeh K, Razavi-Ratki SK, Namiranian N. Effects of Sirolimus on lung function in patients with Lymphangioleiomyomatosis. Caspian J Intern Med. 2019;10(1):7–10.PubMedPubMedCentral
41.
Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Belousova E, Frost MD, Sauter M, Brakemeier S, de Vries PJ, Berkowitz N, et al. Everolimus long-term use in patients with tuberous sclerosis complex: four-year update of the EXIST-2 study. PLoS One. 2017;12(8):e0180939.PubMedPubMedCentralCrossRef
42.
43.
Chilosi M, Pea M, Martignoni G, Brunelli M, Gobbo S, Poletti V, Bonetti F. Cathepsin-k expression in pulmonary lymphangioleiomyomatosis. Mod Pathol. 2009;22(2):161–6.PubMedCrossRef
44.
Sato T, Seyama K, Fujii H, Maruyama H, Setoguchi Y, Iwakami S, Fukuchi Y, Hino O. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet. 2002;47(1):20–8.PubMedCrossRef
45.
Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell. 2010;40(2):310–22.PubMedPubMedCentralCrossRef
46.
Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med. 2011;154(12):797–805 w-292-793.PubMedPubMedCentralCrossRef
47.
Barrera P, Simons SO, Luijk B, Wessels MJ, Heijdra YF. Efficacy of sirolimus therapy for chylous effusions in lymphangioleiomyomatosis. Ann Am Thorac Soc. 2013;10(4):408–9.PubMedCrossRef
48.
Harari S, Elia D, Torre O, Bulgheroni E, Provasi E, Moss J. Sirolimus therapy for patients with Lymphangioleiomyomatosis leads to loss of Chylous ascites and circulating LAM cells. Chest. 2016;150(2):e29–32.PubMedPubMedCentralCrossRef
49.
Ohara T, Oto T, Miyoshi K, Tao H, Yamane M, Toyooka S, Okazaki M, Date H, Sano Y. Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis. Ann Thorac Surg. 2008;86(6):e7–8.PubMedCrossRef
50.
Chachaj A, Drozdz K, Chabowski M, Dziegiel P, Grzegorek I, Wojnar A, Jazwiec P, Szuba A. Chyloperitoneum, chylothorax and lower extremity lymphedema in woman with sporadic lymphangioleiomyomatosis successfully treated with sirolimus: a case report. Lymphology. 2012;45(2):53–7.PubMed
51.
Ando K, Kurihara M, Kataoka H, Ueyama M, Togo S, Sato T, Doi T, Iwakami S, Takahashi K, Seyama K, et al. Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis. Respir Investig. 2013;51(3):175–83.PubMedCrossRef
52.
53.
Ellender CM, Williams TJ, Gooi J, Snell GI, Whitford HM. Management of refractory chylothorax in pulmonary lymphangioleiomyomatosis. Respirology Case Rep. 2015;3(2):72–4.CrossRef
54.
Dancey JE. Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs. 2005;14(3):313–28.PubMedCrossRef
55.
Johnson SR, Chang WY, Tattersfield AE, Lewis S, Kumaran M, Cane JL. Doxycycline in lymphangioleiomyomatosis: not all questions are answered. Eur Respir J. 2014;43(5):1538.PubMedCrossRef
56.
Young L, Lee HS, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, et al. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the multicenter international Lymphangioleiomyomatosis efficacy of Sirolimus (MILES) trial. Lancet Respir Med. 2013;1(6):445–52.PubMedPubMedCentralCrossRef
57.
Xu KF, Tian X, Yang Y, Zhang H. Rapamycin for lymphangioleiomyomatosis: optimal timing and optimal dosage. Thorax. 2018;73(4):308–10.PubMedCrossRef
58.
Harari S, Spagnolo P, Cocconcelli E, Luisi F, Cottin V. Recent advances in the pathobiology and clinical management of lymphangioleiomyomatosis. Curr Opin Pulm Med. 2018;24(5):469–76.PubMedCrossRef
59.
Yao J, Taveira-DaSilva AM, Jones AM, Julien-Williams P, Stylianou M, Moss J. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2014;190(11):1273–82.PubMedPubMedCentralCrossRef
Metadata
Title
The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis
Authors
Qi Wang
Mengqi Luo
Bo Xiang
Siyuan Chen
Yi Ji
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2020
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-020-1316-3

Other articles of this Issue 1/2020

Respiratory Research 1/2020 Go to the issue

Letter to the Editor

A super-spreader of SARS-CoV-2 in incubation period among health-care workers

Research

Cardiometabolic comorbidities in obstructive sleep apnea patients are related to disease severity, nocturnal hypoxemia, and decreased sleep quality

Letter to the Editor

CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis

Research

Value of metalloproteinases in predicting COPD in heavy urban smokers

Research

Airway regulatory T cells are decreased in COPD with a rapid decline in lung function

Research

Prevalence and distribution patterns of allergens among children with asthma and asthma-like symptoms in Shanghai, China

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits